The Biology and Genetics of Marfan Syndrome
At a Glance
Marfan syndrome is caused by mutations in the FBN1 gene, which alters the production of fibrillin-1 and weakens the body's connective tissue. While typically inherited from a parent with a 50% passing chance, up to 30% of cases result from new, spontaneous genetic mutations.
To understand Marfan syndrome, it helps to think of your body’s connective tissue as the scaffolding of a building or the rubber bands in a piece of fabric [1]. This tissue provides the strength and elasticity your body needs to hold everything in place—from your heart and lungs to your skin and joints. In Marfan syndrome, a genetic change causes this scaffolding to be weaker and less stable than it should be [2].
The FBN1 Gene and Fibrillin-1
The instructions for building this scaffolding are contained in a gene called FBN1 [1]. This gene tells your body how to make a protein called fibrillin-1 [3]. These protein molecules normally cluster together to form tiny “microfibrils” that give your tissues their structure and resilience [4].
When the FBN1 gene has a mutation (a “misspelling” in the instructions), the body either produces too little fibrillin-1 or produces a version that doesn’t work correctly [5][6]. As a result, the “rubber bands” in the tissues are more prone to stretching or tearing [2].
The Role of TGF-beta
Fibrillin-1 doesn’t just provide structure; it also acts as a “storage locker” for a powerful growth protein called TGF-beta (transforming growth factor-beta) [4][7].
- Normal Function: Healthy fibrillin-1 holds onto TGF-beta, keeping it inactive until the body needs it [8].
- In Marfan Syndrome: Because the fibrillin-1 is faulty, it cannot hold onto TGF-beta properly. This leads to an overactivation of TGF-beta [3][2].
This excess of TGF-beta tells the body to grow and change in ways it shouldn’t, contributing to the tall stature, long fingers, and changes in the heart’s blood vessels seen in Marfan syndrome [9][10].
How Marfan Syndrome is Inherited
Marfan syndrome follows a pattern called autosomal dominant inheritance [1].
- The 50% Rule: Every person has two copies of the FBN1 gene (one from each parent). If one parent has Marfan syndrome, there is a 50% chance in each pregnancy that the child will inherit the mutated gene [1].
- De Novo (New) Mutations: About 25% to 30% of people with Marfan syndrome are the first in their family to have it [11][12]. This is called a de novo mutation, which happens spontaneously at the time of conception. Once someone has a de novo mutation, they can pass it on to their children following the 50% rule [1].
Why Symptoms Vary (Genotype-Phenotype)
Not all mutations in the FBN1 gene are the same. This helps explain why one person may have very different symptoms than another, even within the same family [13].
Tip: Ask your geneticist or genetic counselor to explain which type of mutation is on your lab report, as this can help connect the science to your actual care plan.
| Mutation Type | Description | Common Clinical Insight |
|---|---|---|
| Haploinsufficiency (HI) | The body produces only half the amount of normal fibrillin-1 [14]. | Sometimes associated with a higher risk of aortic dissection at a younger age [5][15]. |
| Dominant-Negative (DN) | The body makes a “bad” protein that interferes with the “good” protein [5]. | Often more frequently associated with ectopia lentis (lens dislocation) [5][15]. |
| Neonatal Region | Mutations occurring specifically in exons 24–32 [16]. | Can lead to “Neonatal Marfan syndrome,” a very severe form that appears at birth [17][18]. |
Understanding your specific mutation can help your doctors personalize your care and monitoring [13].
Common questions in this guide
What is the FBN1 gene and what does it do?
Is Marfan syndrome always inherited from a parent?
What are the chances of passing Marfan syndrome to my children?
What does haploinsufficiency mean on my Marfan genetic report?
What is a dominant-negative mutation in Marfan syndrome?
Related questions
Get notified when new evidence is published on Marfan syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Clinical Characteristics of Marfan Syndrome in Korea.
Lim AY, Song JS, Kim EK, et al.
Korean circulation journal 2016; (46(6)):841-845 doi:10.4070/kcj.2016.46.6.841.
PMID: 27826344 - 2
Nanoscale Structural Comparison of Fibrillin-1 Microfibrils Isolated from Marfan and Non-Marfan Syndrome Human Aorta.
Șulea CM, Mártonfalvi Z, Csányi C, et al.
International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087561.
PMID: 37108724 - 3
Engineered mutations in fibrillin-1 leading to Marfan syndrome act at the protein, cellular and organismal levels.
Zeyer KA, Reinhardt DP
Mutation research. Reviews in mutation research 2015; (765()):7-18.
PMID: 26281765 - 4
The N-Terminal Region of Fibrillin-1 Mediates a Bipartite Interaction with LTBP1.
Robertson IB, Dias HF, Osuch IH, et al.
Structure (London, England : 1993) 2017; (25(8)):1208-1221.e5 doi:10.1016/j.str.2017.06.003.
PMID: 28669633 - 5
Genotype FBN1/phenotype relationship in a cohort of patients with Marfan syndrome.
Hernándiz A, Zúñiga A, Valera F, et al.
Clinical genetics 2021; (99(2)):269-280 doi:10.1111/cge.13879.
PMID: 33174221 - 6
Betaglycan (TGFBR3) up-regulation correlates with increased TGF-β signaling in Marfan patient fibroblasts in vitro.
Groeneveld ME, Bogunovic N, Musters RJP, et al.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2018; (32()):44-49 doi:10.1016/j.carpath.2017.10.003.
PMID: 29198452 - 7
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Quiñones-Pérez B, VanNoy GE, Towne MC, et al.
American journal of medical genetics. Part A 2018; (176(3)):560-569 doi:10.1002/ajmg.a.38590.
PMID: 29350460 - 8
Co-existence of Marfan syndrome and systemic sclerosis: A case report and a hypothesis suggesting a common link.
Yap WF, Chong HC
International journal of rheumatic diseases 2020; (23(11)):1568-1573 doi:10.1111/1756-185X.13965.
PMID: 32969582 - 9
Ulnar Artery Aneurysm as a Late Sequela of Marfan Syndrome.
Goodenough CJ, Afifi RO, Prakash SK, et al.
The Journal of hand surgery 2020; (45(11)):1090.e1-1090.e5 doi:10.1016/j.jhsa.2020.01.010.
PMID: 32213296 - 10
Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice.
Park JH, Kim MS, Ham S, et al.
Biomolecules & therapeutics 2020; (28(1)):98-103 doi:10.4062/biomolther.2019.042.
PMID: 31284709 - 11
FBN1 gene mutations in 26 Hungarian patients with suspected Marfan syndrome or related fibrillinopathies.
Madar L, Szakszon K, Pfliegler G, et al.
Journal of biotechnology 2019; (301()):105-111 doi:10.1016/j.jbiotec.2019.05.012.
PMID: 31163209 - 12
Novel Marfan Syndrome-Associated Mutation in the FBN1 Gene Caused by Parental Mosaicism and Leading to Abnormal Limb Patterning.
Martínez-Quintana E, Caballero-Sánchez N, Rodríguez-González F, et al.
Molecular syndromology 2017; (8(3)):148-154 doi:10.1159/000467909.
PMID: 28588436 - 13
Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants.
Arnaud P, Milleron O, Hanna N, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(7)):1296-1304 doi:10.1038/s41436-021-01132-x.
PMID: 33731877 - 14
Marfan syndrome: current perspectives.
Pepe G, Giusti B, Sticchi E, et al.
The application of clinical genetics 2016; (9()):55-65 doi:10.2147/TACG.S96233.
PMID: 27274304 - 15
Combining clinical examination with exome sequencing for the diagnosis and treatment of Marfan syndrome: a case series of 6 families from China.
Duan Y, Li P, Ding T, et al.
Annals of palliative medicine 2021; (10(9)):9953-9962 doi:10.21037/apm-21-2305.
PMID: 34628919 - 16
Genotype-phenotype spectrum and prognosis of early-onset Marfan syndrome.
Kemezyte A, Gegieckiene R, Burnyte B
BMC pediatrics 2023; (23(1)):539 doi:10.1186/s12887-023-04357-8.
PMID: 37891508 - 17
Early-onset Marfan syndrome with a novel missense mutation: A case report.
Soma K, Kitagawa Y, Toki T, et al.
Journal of cardiology cases 2023; (27(6)):283-286 doi:10.1016/j.jccase.2023.02.019.
PMID: 37283908 - 18
Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24-32.
Maeda J, Kosaki K, Shiono J, et al.
Heart and vessels 2016; (31(10)):1717-23 doi:10.1007/s00380-016-0793-2.
PMID: 26796135
This page explains the genetics and biology of Marfan syndrome for educational purposes. A genetic counselor or medical geneticist is the best source to interpret your specific genetic test results and family risks.